Biotechnology

IGM Biosciences

IGM Biosciences released FY2025 Semi-Annual earnings on July 31 (EST), actual revenue USD 144.12 M, actual EPS USD 0.7199

IGM Biosciences released FY2025 Q2 earnings on July 31 (EST), actual revenue USD 143.62 M (forecast USD 3.203 M), actual EPS USD 1.5799 (forecast USD -0.3)

Brodsky & Smith Investigating IGM Biosciences' Board for Breach of Duty

IGM Biosciences' Chief Business Officer Disposes of Common Stock

IGM Biosciences Inc reports Q1 EPS loss of 51 cents

IGM Biosciences released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 499K (forecast USD 4.253M), actual EPS USD -0.8647 (forecast USD -0.55)

IGM Biosciences Inc 裁员 80% 因合作终止

IGM Biosciences Inc forecasts Q1 loss of 41 cents per share

IGM Biosciences' Stock Downgraded by US Bank Due to Liquidity Concerns

IGM Biosciences released FY2024 annual earnings on March 6 (EST), actual revenue $2.679M (forecast $2.586M), actual EPS -$3.2355 (forecast -$3.3659)

IGM Biosciences released FY2024 Q4 earnings on March 6 (EST), actual revenue 412 K USD (forecast 393.75 K USD), actual EPS -0.6022 USD (forecast -0.7324 USD)

IGM Biosciences released FY2024 9 Months Earnings on November 8, 2024 (EST), with actual revenue of 2,267,000 USD and EPS of -2.634

IGM Biosciences released FY2024 Q3 earnings on November 8, 2024 (EST), actual revenue $516,000 (forecast $242.22K), actual EPS -1.0127 (forecast -0.8169)

IGM Biotech Announces Strategic Shift to Focus on T Cell Conjugates for Autoimmune Diseases

JPMorgan Chase & Co. raises target price for IGM Biosciences stock

IGM Biosciences Expects Quarterly Revenue to Grow 45.5%

Financial analysts rate IGM Biosciences

RBC Capital reiterates Outperform rating on IGM Biosciences

IGM Biological Sciences Company reports a per-share loss that exceeds analysts' expectations by 1.94%.

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

Gulf Resources

DigitalBridge

Toro

Dreamland

Lichen

Springview

Alumis

ADMA生物制藥

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制藥

OpGen

福泰制藥

再生元制藥

阿里拉姆制藥

Argenx

百濟神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap